Leqvio® (inclisiran) – Updated indication
July 10, 2023 - Novartis announced the FDA approval of Leqvio (inclisiran), as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).
Top